Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
CM.5.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
CM.8.1.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBSNNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BN.1.2.8NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XAHNNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.5.2.5NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBJ.3NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
EP.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.4.1.5NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.2.4NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
FF.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
DN.1.1.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.626NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.629NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
GA.9NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AY.61 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.2.75.6NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
GC.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BQ.1.1.16NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.524NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.5.2.38NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
FQ.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
JB.1.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBB.1.17NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
FL.3.4NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
FZ.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
DV.7.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
FL.6NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
FL.30.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBB.1.5.68NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
CD.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AY.122.3 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.1.1.3NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AY.43.6 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBF.4NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.2.27NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AY.43.9 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XUNNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.3 (Omicron)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.3.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.1.16.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.372NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.128NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.36.33NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.405NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.296NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.412NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AC.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
C.27NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.421NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used